What Cullinan Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 2 | 28 |
| Total trades | 4 | 40 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 34,000 | 184,288 |
| Disposed | 38,000 | 165,912 |
| Net activity | −4,000 | +18,376 |
Common stock only — 1 reported trade in the last 12 months is in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer | Sep 08 | Open-market sale · S | −8,000 | $21.57 | −$173K | 158,844 |
| Michaelson Jennifer | Chief Scientific Officer | Sep 08 | Exercise / conversion · M | +4,000 | $4.30 | +$17.2K | 166,844 |
| Michaelson Jennifer | Chief Scientific Officer | Aug 13 | Open-market sale · S | −30,000 | $20.26 | −$608K | 162,844 |
| Michaelson Jennifer | Chief Scientific Officer | Aug 13 | Exercise / conversion · M | +30,000 | $4.30 | +$129K | 192,844 |
| Michaelson Jennifer | Chief Scientific Officer | Jul 06 | Open-market sale · S | −8,000 | $17.82 | −$143K | 162,844 |
| Michaelson Jennifer | Chief Scientific Officer | Jul 06 | Exercise / conversion · M | +4,000 | $4.30 | +$17.2K | 170,844 |
| Fenton Mary Kay | Chief Financial Officer | Jun 30 | Grant / award · A | +1,541 | $8.60 | +$13.3K | 127,921 |
| Sumer Jacquelyn L | Chief Legal Officer | Jun 30 | Grant / award · A | +2,470 | $8.60 | +$21.2K | 130,559 |
| Michaelson Jennifer | Chief Scientific Officer | May 05 | Open-market sale · S | −200 | $15.58 | −$3.12K | 166,844 |
| Michaelson Jennifer | Chief Scientific Officer | May 05 | Open-market sale · S | −7,800 | $14.60 | −$114K | 167,044 |
| Michaelson Jennifer | Chief Scientific Officer | May 05 | Exercise / conversion · M | +4,000 | $4.30 | +$17.2K | 174,844 |
| Michaelson Jennifer | Chief Scientific Officer | Mar 05 | Open-market sale · S | −8,000 | $15.68 | −$125K | 170,844 |
| Michaelson Jennifer | Chief Scientific Officer | Mar 05 | Exercise / conversion · M | +4,000 | $4.30 | +$17.2K | 178,844 |
| Michaelson Jennifer | Chief Scientific Officer | Feb 25 | Open-market sale · S | −1,780 | $14.14 | −$25.2K | 174,844 |
| Michaelson Jennifer | Chief Scientific Officer | Feb 24 | Open-market sale · S | −3,601 | $14.47 | −$52.1K | 176,624 |
| Sumer Jacquelyn L | Chief Legal Officer | Feb 24 | Open-market sale · S | −3,601 | $14.47 | −$52.1K | 128,089 |
| Ahmed Nadim | President and CEO | Feb 24 | Open-market sale · S | −13,515 | $14.47 | −$196K | 390,803 |
| Jones Jeffrey Alan | Chief Medical Officer | Feb 24 | Open-market sale · S | −4,582 | $14.47 | −$66.3K | 159,968 |
| Michaelson Jennifer | Chief Scientific Officer | Feb 23 | Open-market sale · S | −1,752 | $13.99 | −$24.5K | 180,225 |
| Fenton Mary Kay | Chief Financial Officer | Feb 20 | Open-market sale · S | −4,398 | $13.62 | −$59.9K | 126,380 |
Loading...
